$ONC
BeiGene, Ltd.

2023 Q3 Form 10-Q Financial Statement

#000165130823000127 Filed on August 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $781.3M $595.3M
YoY Change 101.56% 74.27%
Cost Of Revenue $96.31M $95.99M
YoY Change 25.82% 34.87%
Gross Profit $685.0M $499.3M
YoY Change 120.2% 84.64%
Gross Profit Margin 87.67% 83.87%
Selling, General & Admin $364.4M $395.0M
YoY Change 12.86% 19.2%
% of Gross Profit 53.2% 79.12%
Research & Development $453.3M $422.8M
YoY Change 6.31% 11.78%
% of Gross Profit 66.17% 84.68%
Depreciation & Amortization $19.24M $21.31M
YoY Change 26.48% 47.34%
% of Gross Profit 2.81% 4.27%
Operating Expenses $817.7M $817.8M
YoY Change 9.13% 15.25%
Operating Profit -$134.0M -$318.7M
YoY Change -69.44% -27.47%
Interest Expense -$12.33M -$406.4M
YoY Change -98.56% -50.21%
% of Operating Profit
Other Income/Expense, Net $336.7M -$63.82M
YoY Change -367.95% -50.76%
Pretax Income $229.3M -$367.5M
YoY Change -141.6% -34.1%
Income Tax $13.93M $13.67M
% Of Pretax Income 6.07%
Net Earnings $215.4M -$381.1M
YoY Change -138.64% -33.3%
Net Earnings / Revenue 27.57% -64.03%
Basic Earnings Per Share $0.16 -$0.28
Diluted Earnings Per Share $0.15 -$0.28
COMMON SHARES
Basic Shares Outstanding 1.376B shares 1.363B shares
Diluted Shares Outstanding 1.390B shares 1.360B shares

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.34B $24.77B
YoY Change -22.89% -10.91%
Cash & Equivalents $3.067B $3.410B
Short-Term Investments $4.432B $6.126B
Other Short-Term Assets $2.407B $2.615B
YoY Change -71.74% -77.7%
Inventory $316.9M $321.3M
Prepaid Expenses
Receivables $309.1M $299.3M
Other Receivables $309.2M $253.9M
Total Short-Term Assets $4.054B $4.401B
YoY Change -29.49% -30.64%
LONG-TERM ASSETS
Property, Plant & Equipment $1.178B $1.032B
YoY Change 72.75% 63.0%
Goodwill $109.0K
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments $27.33M $30.02M
YoY Change 5.96% 10.77%
Other Assets $140.9M $147.5M
YoY Change 0.25% 12.67%
Total Long-Term Assets $1.471B $1.327B
YoY Change 50.62% 28.57%
TOTAL ASSETS
Total Short-Term Assets $4.054B $4.401B
Total Long-Term Assets $1.471B $1.327B
Total Assets $5.525B $5.729B
YoY Change -17.86% -22.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $341.9M $267.0M
YoY Change 35.62% 13.92%
Accrued Expenses $505.8M $455.0M
YoY Change 23.3% 0.17%
Deferred Revenue $0.00 $159.0M
YoY Change -100.0% -2.67%
Short-Term Debt $2.224B $2.908B
YoY Change -25.29% 20.64%
Long-Term Debt Due 2.399B cnies 3.053B cnies
YoY Change 443.6% 19.72%
Total Short-Term Liabilities $1.283B $1.405B
YoY Change -9.07% 0.48%
LONG-TERM LIABILITIES
Long-Term Debt 1.478B cnies 1.504B cnies
YoY Change 610.55% 21.25%
Other Long-Term Liabilities $41.99M $43.12M
YoY Change -7.05% -10.97%
Total Long-Term Liabilities $478.3M $525.1M
YoY Change -27.47% -22.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.283B $1.405B
Total Long-Term Liabilities $478.3M $525.1M
Total Liabilities $1.762B $1.930B
YoY Change -14.93% -7.01%
SHAREHOLDERS EQUITY
Retained Earnings -$7.594B -$7.810B
YoY Change 14.46% 30.78%
Common Stock $135.0K $137.0K
YoY Change 0.0% 2.24%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.763B $3.799B
YoY Change
Total Liabilities & Shareholders Equity $5.525B $5.729B
YoY Change -17.86% -22.36%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income $215.4M -$381.1M
YoY Change -138.64% -33.3%
Depreciation, Depletion And Amortization $19.24M $21.31M
YoY Change 26.48% 47.34%
Cash From Operating Activities -$297.8M -$1.526B
YoY Change -90.46% 10.88%
INVESTING ACTIVITIES
Capital Expenditures $1.180B $1.006B
YoY Change -263.1% -316.47%
Acquisitions
YoY Change
Other Investing Activities $1.359B $2.113B
YoY Change -7.83% -57.86%
Cash From Investing Activities $178.1M $1.107B
YoY Change -76.26% -75.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -597.0M 1.098B
YoY Change -179.57% -827.69%
NET CHANGE
Cash From Operating Activities -297.8M -1.526B
Cash From Investing Activities 178.1M 1.107B
Cash From Financing Activities -597.0M 1.098B
Net Change In Cash -716.7M 678.5M
YoY Change -55.79% -77.55%
FREE CASH FLOW
Cash From Operating Activities -$297.8M -$1.526B
Capital Expenditures $1.180B $1.006B
Free Cash Flow -$1.478B -$2.532B
YoY Change -38.35% 177.82%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1513000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
5277000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1031938000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
845946000 usd
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
99422000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
109960000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
46895000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
40616000 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
147549000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
170413000 usd
CY2023Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
1327317000 usd
CY2022Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
1172212000 usd
CY2023Q2 us-gaap Assets
Assets
5728736000 usd
CY2022Q4 us-gaap Assets
Assets
6379290000 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
266975000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
294781000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
454950000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
467352000 usd
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
159034000 usd
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
213861000 usd
CY2023Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
17074000 usd
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
25189000 usd
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
23508000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
24041000 usd
CY2023Q2 bgne Research And Development Cost Share Liability Current Portion
ResearchAndDevelopmentCostShareLiabilityCurrentPortion
62516000 usd
CY2022Q4 bgne Research And Development Cost Share Liability Current Portion
ResearchAndDevelopmentCostShareLiabilityCurrentPortion
114335000 usd
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
421052000 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
328969000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1405109000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1468528000 usd
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
207426000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
209148000 usd
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
24276000 usd
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
42026000 usd
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
25821000 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
34517000 usd
CY2023Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
15652000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
15996000 usd
CY2023Q2 bgne Research And Development Cost Share Liability Noncurrent Portion
ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion
208775000 usd
CY2022Q4 bgne Research And Development Cost Share Liability Noncurrent Portion
ResearchAndDevelopmentCostShareLiabilityNoncurrentPortion
179625000 usd
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
43118000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
46095000 usd
CY2023Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
525068000 usd
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
527407000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
1930177000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
1995935000 usd
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
9500000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
9500000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1356140180 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1356140180 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
137000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
135000 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11752019000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
11540979000 usd
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-143687000 usd
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-77417000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7809910000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-7080342000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3798559000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
4383355000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5728736000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6379290000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1043062000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
648198000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
177779000 usd
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
136410000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
831348000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
768122000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
723533000 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
625976000 usd
bgne Amortization Of Intangible Assets Included In Operating Expenses
AmortizationOfIntangibleAssetsIncludedInOperatingExpenses
375000 usd
bgne Amortization Of Intangible Assets Included In Operating Expenses
AmortizationOfIntangibleAssetsIncludedInOperatingExpenses
376000 usd
us-gaap Costs And Expenses
CostsAndExpenses
1733035000 usd
us-gaap Costs And Expenses
CostsAndExpenses
1530884000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-689973000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-882686000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
31086000 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
21502000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-45515000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-117650000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-704402000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-978834000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
25166000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
22090000 usd
us-gaap Net Income Loss
NetIncomeLoss
-729568000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1000924000 usd
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1360224377 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1336463026 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1357211308 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1334252648 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1334252648 shares
CY2023Q2 bgne Earnings Per American Depository Share Diluted
EarningsPerAmericanDepositoryShareDiluted
-3.64
CY2022Q2 bgne Earnings Per American Depository Share Basic
EarningsPerAmericanDepositoryShareBasic
-5.50
bgne Earnings Per American Depository Share Basic
EarningsPerAmericanDepositoryShareBasic
-6.99
bgne Earnings Per American Depository Share Basic
EarningsPerAmericanDepositoryShareBasic
-9.75
bgne Earnings Per American Depository Share Diluted
EarningsPerAmericanDepositoryShareDiluted
-9.75
CY2023Q2 bgne Weighted Average Number Of American Depository Shares Outstanding Diluted
WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted
104632644 shares
CY2022Q2 bgne Weighted Average Number Of American Depository Shares Outstanding Basic
WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic
102804848 shares
bgne Weighted Average Number Of American Depository Shares Outstanding Basic
WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic
104400870 shares
bgne Weighted Average Number Of American Depository Shares Outstanding Basic
WeightedAverageNumberOfAmericanDepositorySharesOutstandingBasic
102634819 shares
bgne Weighted Average Number Of American Depository Shares Outstanding Diluted
WeightedAverageNumberOfAmericanDepositorySharesOutstandingDiluted
102634819 shares
us-gaap Net Income Loss
NetIncomeLoss
-729568000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1000924000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-73172000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-88085000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
6902000 usd
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-12315000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-795838000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1101324000 usd
us-gaap Net Income Loss
NetIncomeLoss
-729568000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1000924000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
42346000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
32061000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
178693000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
146860000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-2178000 usd
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-23529000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
767000 usd
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
6360000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
131923000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-307430000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
53598000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
31633000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
30627000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-32335000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-32678000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-30362000 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-8082000 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
21168000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-72577000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-76737000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
88000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1581000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-857665000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-616522000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
247055000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
95421000 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
0 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
11582000 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
11504000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
567500000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1051028000 usd
bgne Payments To Purchase In Process Research And Development
PaymentsToPurchaseInProcessResearchAndDevelopment
0 usd
bgne Payments To Purchase In Process Research And Development
PaymentsToPurchaseInProcessResearchAndDevelopment
75000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
308863000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
869103000 usd
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
15771000 usd
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
0 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
161846000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
67586000 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
66574000 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
115405000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
35169000 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
18972000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
146212000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-28847000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-50873000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-71212000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-453463000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
152522000 usd
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3410368000 usd
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4531137000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
9693000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
333000 usd
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
1513000 usd
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
3939000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
32529000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
24436000 usd
us-gaap Interest Paid Net
InterestPaidNet
10015000 usd
us-gaap Interest Paid Net
InterestPaidNet
12899000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
95404000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
58676000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
75322000 usd
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
18403000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-348431000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
4157306000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
3692000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
103371000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-84673000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-381137000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
3798559000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
6132563000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
152000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
11880000 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
65555000 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-496000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-435198000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
5774152000 usd
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
7092000 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
81305000 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-99904000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-565726000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
5196919000 usd
CY2023Q2 bgne Number Of Approved Medicines
NumberOfApprovedMedicines
3 medicine
CY2023Q2 bgne Clinical Trials Conducted
ClinicalTrialsConducted
120 trial
CY2023Q2 bgne Number Of Patients
NumberOfPatients
21000 patient
CY2023Q2 bgne Number Of Regions
NumberOfRegions
45 region
CY2023Q2 bgne Product Candidate
ProductCandidate
3 product
CY2023Q2 dei Entity Number Of Employees
EntityNumberOfEmployees
10000 employee
us-gaap Use Of Estimates
UseOfEstimates
Use of estimatesThe preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Areas where management uses subjective judgment include, but are not limited to, estimating the useful lives of long-lived assets, estimating variable consideration in product sales and collaboration revenue arrangements, identifying separate accounting units and determining the standalone selling price of each performance obligation in the Company’s revenue arrangements, assessing the impairment of long-lived assets, valuation and recognition of share-based compensation expenses, realizability of deferred tax assets, estimating uncertain tax positions, valuation of inventory, estimating the allowance for credit losses, determining defined benefit pension plan obligations, measurement of right-of-use assets and lease liabilities and the fair value of financial instruments. Management bases the estimates on historical experience, known trends and various other assumptions that are believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities and reported amounts of revenues and expenses. Actual results could differ from these estimates.
CY2023Q2 bgne Debt Securities Available For Sale Excluding Accrued Interest Number Of Issuing Companies Held
DebtSecuritiesAvailableForSaleExcludingAccruedInterestNumberOfIssuingCompaniesHeld
2 company
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revision of prior period financial statements </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company evaluates the recoverability of its deferred tax assets on a jurisdiction-by-jurisdiction basis by assessing the adequacy of future expected taxable income from all sources, including reversal of temporary differences, forecasted operating earnings and available tax planning strategies in accordance with ASC 740. This assessment is subject to a high degree of subjectivity, as the sources of income rely heavily on estimates that are based on a number of factors, including historical experience and short-range and long-range business forecasts. A valuation allowance is provided when the Company determines that it is more-likely-than-not that some portion or all of a deferred tax asset will not be realized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Prior to the third quarter of 2022, the Company determined that the majority of its net deferred tax assets (primarily in the U.S.) were realizable on a more-likely-than-not basis, primarily due to cumulative pre-tax income at the taxpaying entity and the weighting of available positive and negative evidence. Accordingly, no valuation allowance was previously recorded related to those deferred tax assets. In October 2022, in connection with the preparation of its condensed consolidated financial statements for the three and nine months ended September 30, 2022, the Company reassessed its position on the realizability of its net deferred tax assets and determined that the negative evidence associated with cumulative losses at the consolidated financial statement level are not able to be overcome by other positive evidence, and therefore, a valuation allowance should be applied to its net deferred tax asset balance. The Company determined the previous conclusion to not apply a valuation allowance to certain net deferred tax assets was an error. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In accordance with Staff Accounting Bulletin (SAB) No. 99, “Materiality,” and SAB No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,” the Company evaluated the error and determined that the related impact was not material to any of its previously issued financial statements, but that correcting the cumulative impact of the error would be significant to its statements of operations for the three and nine months ended September 30, 2022. Accordingly, the Company has revised the three and six months ended June 30, 2022 condensed consolidated financial statements and related notes included herein to record a valuation allowance against the Company’s net deferred tax asset balance for all periods presented. A summary of revisions to previously reported financial statements is presented in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Revision of Prior Period Financial Statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Note 9, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and Note 13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> have been updated to reflect the revision. The Company will also correct previously reported financial information for this error in its future filings, as applicable.</span></div>
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8141000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
22090000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-565726000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1000924000 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.42
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.42
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
CY2022Q2 bgne Earnings Per American Depository Share Basic
EarningsPerAmericanDepositoryShareBasic
-5.50
CY2022Q2 bgne Earnings Per American Depository Share Diluted
EarningsPerAmericanDepositoryShareDiluted
-5.50
bgne Earnings Per American Depository Share Basic
EarningsPerAmericanDepositoryShareBasic
-9.75
bgne Earnings Per American Depository Share Diluted
EarningsPerAmericanDepositoryShareDiluted
-9.75
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-565726000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1000924000 usd
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-665630000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1101324000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1000924000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
555000 usd
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-32335000 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
21168000 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1581000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-616522000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
6132563000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-435198000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
5774152000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-565726000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
5196919000 usd
CY2022Q1 bgne Number Of Products Initiated Marketing And Promotion
NumberOfProductsInitiatedMarketingAndPromotion
5 product
CY2022Q1 bgne Number Of Products Initiated Marketing And Promotion
NumberOfProductsInitiatedMarketingAndPromotion
5 product
CY2023Q2 bgne Number Of Ongoing Trials
NumberOfOngoingTrials
2 trial
CY2023Q2 bgne Reimbursement Expense
ReimbursementExpense
15310000 usd
CY2022Q2 bgne Reimbursement Expense
ReimbursementExpense
10555000 usd
bgne Reimbursement Expense
ReimbursementExpense
26893000 usd
bgne Reimbursement Expense
ReimbursementExpense
22266000 usd
CY2023Q2 us-gaap Restricted Cash
RestrictedCash
11206000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
5473000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
107802000 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2023Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2109000 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
105693000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Amortized Cost Excluding Accrued Interest After Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
674262000 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0 usd
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
9011000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Excluding Accrued Interest Current
DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
665251000 usd
CY2023Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
59209000 usd
CY2022Q4 us-gaap Equity Securities Without Readily Determinable Fair Value Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
57054000 usd
CY2023Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
0 usd
us-gaap Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
1081000 usd
us-gaap Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
366000 usd
CY2022Q2 us-gaap Equity Securities Without Readily Determinable Fair Value Upward Price Adjustment Annual Amount
EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount
366000 usd
CY2023Q2 us-gaap Equity Method Investments
EquityMethodInvestments
30020000 usd
CY2022Q4 us-gaap Equity Method Investments
EquityMethodInvestments
27710000 usd
CY2023Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
109048000 usd
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
88957000 usd
CY2023Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
31472000 usd
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
20886000 usd
CY2023Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
180813000 usd
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
172503000 usd
CY2023Q2 us-gaap Inventory Net
InventoryNet
321333000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
282346000 usd
CY2023Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
749038000 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
723789000 usd
CY2023Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
201406000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
171470000 usd
CY2023Q2 us-gaap Construction In Progress Gross
ConstructionInProgressGross
484306000 usd
CY2022Q4 us-gaap Construction In Progress Gross
ConstructionInProgressGross
293627000 usd
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1031938000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
845946000 usd
CY2023Q2 us-gaap Depreciation
Depreciation
21307000 usd
us-gaap Depreciation
Depreciation
40332000 usd
CY2022Q2 us-gaap Depreciation
Depreciation
14461000 usd
us-gaap Depreciation
Depreciation
30041000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
57704000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
10809000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
46895000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
49551000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
8935000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
40616000 usd
CY2023Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1028000 usd
CY2022Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1000000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2014000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2020000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
2232000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
4464000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
4464000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
4464000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
4214000 usd
CY2023Q2 bgne Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
27057000 usd
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
46895000 usd
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13674000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
25166000 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8141000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
22090000 usd
CY2023Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
12524000 usd
CY2023Q2 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
559000 usd
us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
969000 usd
CY2023Q2 bgne Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
72391000 usd
CY2022Q4 bgne Prepaid Research And Development Costs
PrepaidResearchAndDevelopmentCosts
71488000 usd
CY2023Q2 bgne Prepaid Manufacturing Costs
PrepaidManufacturingCosts
69319000 usd
CY2022Q4 bgne Prepaid Manufacturing Costs
PrepaidManufacturingCosts
58950000 usd
CY2023Q2 us-gaap Prepaid Taxes
PrepaidTaxes
18485000 usd
CY2022Q4 us-gaap Prepaid Taxes
PrepaidTaxes
20478000 usd
CY2023Q2 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
36866000 usd
CY2022Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
22777000 usd
CY2023Q2 us-gaap Interest Receivable Current
InterestReceivableCurrent
1992000 usd
CY2022Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
3039000 usd
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
7593000 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
3664000 usd
CY2023Q2 bgne Short Term Deposits
ShortTermDeposits
7198000 usd
CY2022Q4 bgne Short Term Deposits
ShortTermDeposits
1510000 usd
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
41206000 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
34647000 usd
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
255050000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
216553000 usd
CY2023Q2 us-gaap Goodwill
Goodwill
109000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
109000 usd
CY2023Q2 bgne Prepayment Of Long Term Asset
PrepaymentOfLongTermAsset
13140000 usd
CY2022Q4 bgne Prepayment Of Long Term Asset
PrepaymentOfLongTermAsset
22025000 usd
CY2023Q2 bgne Prepaid Supply Cost
PrepaidSupplyCost
30539000 usd
CY2022Q4 bgne Prepaid Supply Cost
PrepaidSupplyCost
48642000 usd
CY2023Q2 us-gaap Value Added Tax Receivable Noncurrent
ValueAddedTaxReceivableNoncurrent
1734000 usd
CY2022Q4 us-gaap Value Added Tax Receivable Noncurrent
ValueAddedTaxReceivableNoncurrent
804000 usd
CY2023Q2 bgne Rental Deposits And Other
RentalDepositsAndOther
6420000 usd
CY2022Q4 bgne Rental Deposits And Other
RentalDepositsAndOther
7054000 usd
CY2023Q2 us-gaap Long Term Investments
LongTermInvestments
95607000 usd
CY2022Q4 us-gaap Long Term Investments
LongTermInvestments
91779000 usd
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
147549000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
170413000 usd
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
135719000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
184775000 usd
CY2023Q2 bgne Accrued Liabilities External Research And Development
AccruedLiabilitiesExternalResearchAndDevelopment
91108000 usd
CY2022Q4 bgne Accrued Liabilities External Research And Development
AccruedLiabilitiesExternalResearchAndDevelopment
139168000 usd
CY2023Q2 bgne Accrued Expenses Commercial Activities
AccruedExpensesCommercialActivities
65506000 usd
CY2022Q4 bgne Accrued Expenses Commercial Activities
AccruedExpensesCommercialActivities
51806000 usd
CY2023Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
38486000 usd
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
18815000 usd
CY2023Q2 bgne Accrued Sales Rebates And Returns Current
AccruedSalesRebatesAndReturnsCurrent
85591000 usd
CY2022Q4 bgne Accrued Sales Rebates And Returns Current
AccruedSalesRebatesAndReturnsCurrent
41817000 usd
CY2023Q2 bgne Accrued Professional Fees And Other Current
AccruedProfessionalFeesAndOtherCurrent
38540000 usd
CY2022Q4 bgne Accrued Professional Fees And Other Current
AccruedProfessionalFeesAndOtherCurrent
30971000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
454950000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
467352000 usd
CY2023Q2 bgne Government Grants Or Incentives Received And Deferred Noncurrent
GovernmentGrantsOrIncentivesReceivedAndDeferredNoncurrent
34865000 usd
CY2022Q4 bgne Government Grants Or Incentives Received And Deferred Noncurrent
GovernmentGrantsOrIncentivesReceivedAndDeferredNoncurrent
38176000 usd
CY2023Q2 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
7996000 usd
CY2022Q4 us-gaap Defined Benefit Pension Plan Liabilities Noncurrent
DefinedBenefitPensionPlanLiabilitiesNoncurrent
7760000 usd
CY2023Q2 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
257000 usd
CY2022Q4 us-gaap Other Sundry Liabilities Noncurrent
OtherSundryLiabilitiesNoncurrent
159000 usd
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
43118000 usd
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
46095000 usd
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
421052000 usd
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
3053095000 cny
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
328969000 usd
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
2268905000 cny
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
207426000 usd
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1504071000 cny
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
209148000 usd
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1442500000 cny
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
4891000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
9465000 usd
CY2023Q2 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
428000 usd
us-gaap Interest Costs Capitalized
InterestCostsCapitalized
772000 usd
CY2022Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
5456000 usd
us-gaap Interest Expense Debt
InterestExpenseDebt
10984000 usd
CY2022Q2 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
654000 usd
us-gaap Interest Costs Capitalized
InterestCostsCapitalized
1935000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-381137000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-565726000 usd
us-gaap Net Income Loss
NetIncomeLoss
-729568000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1000924000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1360224377 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1360224377 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1336463026 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1336463026 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1357211308 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1357211308 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1334252648 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1334252648 shares
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
103329000 usd
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
81305000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
178717000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
110624000 usd
us-gaap Other Comprehensive Income Loss Before Reclassifications Net Of Tax
OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
-66270000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-66270000 usd
CY2023Q2 bgne Restricted Net Assets Minimum Required Statutory Reserve Of Annual After Tax Profit Percentage
RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage
0.10
CY2023Q2 bgne Restricted Net Assets Required Statutory Reserve As Percentage Of Registered Capital
RestrictedNetAssetsRequiredStatutoryReserveAsPercentageOfRegisteredCapital
0.50
CY2023Q2 bgne Restricted Net Assets Minimum Required Statutory Reserve Of Annual After Tax Profit Percentage
RestrictedNetAssetsMinimumRequiredStatutoryReserveOfAnnualAfterTaxProfitPercentage
0.10
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
104115000 usd
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
true
CY2023Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false

Files In Submission

Name View Source Status
0001651308-23-000127-index-headers.html Edgar Link pending
0001651308-23-000127-index.html Edgar Link pending
0001651308-23-000127.txt Edgar Link pending
0001651308-23-000127-xbrl.zip Edgar Link pending
bgne-20230630.htm Edgar Link pending
bgne-20230630.xsd Edgar Link pending
bgne-20230630_g1.jpg Edgar Link pending
bgne-20230630_cal.xml Edgar Link unprocessable
bgne-20230630_def.xml Edgar Link unprocessable
bgne-20230630_htm.xml Edgar Link completed
bgnelogo_rgb.jpg Edgar Link pending
exhibit1010beigene-formofn.htm Edgar Link pending
exhibit101mutualterminatio.htm Edgar Link pending
exhibit102facilityagreemen.htm Edgar Link pending
exhibit103chanlee-offerlet.htm Edgar Link pending
exhibit104aremploymentappo.htm Edgar Link pending
exhibit105beigene-rsuaward.htm Edgar Link pending
exhibit106beigene-rsuaward.htm Edgar Link pending
exhibit107beigene-rsuaward.htm Edgar Link pending
exhibit108beigene-nqstocko.htm Edgar Link pending
exhibit109beigene-formofno.htm Edgar Link pending
exhibit311-2023q2.htm Edgar Link pending
exhibit312-2023q2.htm Edgar Link pending
exhibit321-2023q2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
bgne-20230630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
bgne-20230630_lab.xml Edgar Link unprocessable